Dec 2024 $25 M No. 5 $10 to $50 million 109
ReAlta Life Sciences, Inc.: Raise no. 5, Dec 2024 × Investors in this round 109 investors had bought by the notice of May 21, 2025: 109 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $25 M of $25 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Shares of Series A-6 Preferred Stock and underlying shares of common stock issuable upon conversion thereof Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Marek · Executive Officer, Director John Rickman · Executive Officer Kenji Cunnion · Executive Officer Neel Krishna · Executive Officer Paolo Martini · Executive Officer Andrew Miller · Director Christi Shaw · Director Edward Heidt, Jr. · Director Emma Reeve · Director Frank Gadams · Director Laurie Glimcher · Director Lewis Williams · Director Mert Aktar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John Rickman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 21, 2025. Read the notice at the SEC .
equity SEC Nov 2023 $30 M No. 4 $10 to $50 million 149
ReAlta Life Sciences, Inc.: Raise no. 4, Nov 2023 × Investors in this round 149 investors had bought by the notice of May 21, 2025: 149 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity, other: Shares of Series A-5 Preferred Stock and underlying shares of common stock issuable upon conversion thereof Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Marek · Executive Officer, Director John Rickman · Executive Officer Kenji Cunnion · Executive Officer Neel Krishna · Executive Officer Paolo Martini · Executive Officer Andrew Miller · Director Christi Shaw · Director Edward Heidt, Jr. · Director Emma Reeve · Director Frank Gadams · Director Laurie Glimcher · Director Lewis Williams · Director Mert Aktar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John Rickman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 21, 2025. Read the notice at the SEC .
equity SEC Feb 2023 $12 M No. 3 $10 to $50 million 85
ReAlta Life Sciences, Inc.: Raise no. 3, Feb 2023 × Investors in this round 85 investors had bought by the notice of May 21, 2025: 85 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $12 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Shares of Series A-4 Preferred Stock and underlying shares of common stock issuable upon conversion thereof Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Marek · Executive Officer, Director John Rickman · Executive Officer Kenji Cunnion · Executive Officer Neel Krishna · Executive Officer Paolo Martini · Executive Officer Andrew Miller · Director Christi Shaw · Director Edward Heidt, Jr. · Director Emma Reeve · Director Frank Gadams · Director Laurie Glimcher · Director Lewis Williams · Director Mert Aktar · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John Rickman, Chief Financial Officer. Source: SEC Form D, newest notice filed May 21, 2025. Read the notice at the SEC .
equity SEC Dec 2020 $23 M No. 2 $10 to $50 million 92
ReAlta Life Sciences, Inc.: Raise no. 2, Dec 2020 × Investors in this round 92 investors had bought by the notice of Sep 13, 2023: 92 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $23 M of $23 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Shares of Series A-3 Preferred Stock and underlying shares of common stock issuable upon conversion thereof Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Rickman · Executive Officer Kathryn Abshire · Executive Officer Kenji Cunnion · Executive Officer, Director Neel Krishna · Executive Officer Ulrich Thienel · Executive Officer, Director Azmi Nabulsi · Director Barry Strasnick · Director Christine Neikirk · Director Deborah Geraghty · Director Edward Heidt, Jr. · Director Frank Gadams · Director Jonathan Zalevsky · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Ulrich Thienel, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 13, 2023. Read the notice at the SEC .
equity SEC Sep 2018 $5 M No. 1 $2 to $10 million 1
ReAlta Life Sciences, Inc.: Raise no. 1, Sep 2018 × Investors in this round 1 investor had bought by the notice of Sep 12, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $12 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $14,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kenji Kerry Cunnion · Executive Officer, Director · Director and Chief Medical Officer Neel Kerry Krishna · Executive Officer · Chief Science Officer Thomas Kerry McCarter · Executive Officer · Managing Director Edward Kerry Heidt, Jr. · Director Jerry Kerry Nadler · Director John Kerry Harding · Director Ulrich Kerry Thienel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Thomas Kerry McCarter, Managing Director. Source: SEC Form D, newest notice filed Sep 12, 2018. Read the notice at the SEC .
equity SEC